第五届监事会第十三次会议决议的公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导 性陈述或重大遗漏。 证券代码：002589 证券简称：瑞康医药 公告编号：2025-018 瑞康医药集团股份有限公司 瑞康医药集团股份有限公司（以下简称"公司"）第五届监事会第十三次会议 通知于 2025 年 4 月 20 日以书面形式发出，2025 年 4 月 23 日上午在烟台市芝罘 区凤鸣路 103 号 13 号楼会议室以现场及通讯表决的方式召开。会议由张岩女士 主持，会议应出席监事 3 名，实际出席监事 3 名。会议的召开符合《中华人民共 和国公司法》和《公司章程》的规定。经与会监事审议，会议形成如下决议： 一、审议通过《公司 2024 年年度报告及其摘要》 经审核，《公司 2024 年年度报告及其摘要》符合《公司法》、《证券法》、 《上市公司信息披露管理办法》等相关规定，报告内容真实、准确、完整地反映 了公司 2024 年年度的经营状况，不存在任何虚假记载、误导性陈述或者重大遗 漏。 《公司 2024 年年度报告》及《公司 2024 年年度报告摘要》的内容全文刊登 于巨潮资讯网（http ...

证券代码：002589 证券简称：瑞康医药 公告编号：2025-022 瑞康医药集团股份有限公司（以下简称"公司"、"瑞康医药"）第五届董事会 第十四次会议通知于 2025 年 4 月 20 日以书面形式发出，2025 年 4 月 23 日上午 在烟台市芝罘区凤鸣路 103 号 13 号楼会议室以现场及通讯表决的方式召开。会 议由董事长韩旭先生主持，会议应出席董事 9 名，实际出席董事 9 名，公司监事 列席会议。本次会议的召开符合《中华人民共和国公司法》等法律、法规和《公 司章程》的规定。本次会议经有效表决，形成如下决议： 一、审议通过《公司 2024 年年度报告及其摘要》 经审核，《公司 2024 年年度报告及其摘要》符合《公司法》、《证券法》、 《上市公司信息披露管理办法》等相关规定，报告内容真实、准确、完整地反映 了公司 2024 年年度的经营状况，不存在任何虚假记载、误导性陈述或者重大遗 漏。 第五届董事会第十四次会议决议的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导 性陈述或重大遗漏。 《公司 2024 年年度报告》及《公司 2024 年年度报告摘要》的内容全 ...

证券代码：002589 证券简称：瑞康医药 公告编号：2025-019 瑞康医药集团股份有限公司 关于2024年度利润分配预案的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导 性陈述或重大遗漏。 瑞康医药集团股份有限公司（以下简称"公司"、"瑞康医药"）于 2025 年 4 月 23 日召开第五届董事会第十四次会议、第五届监事会第十三次会议，分别审议 通过了公司《2024 年年度利润分配预案》，本次利润分配预案尚需提交公司 2024 年年度股东大会审议。现将具体情况公告如下： 一、2024 年度利润分配预案的具体情况 经中兴财光华会计师事务所（特殊普通合伙）审计确认，公司 2024 年度归 属于上市公司股东的净利润为 20,621,581.94 元,其中母公司未分配利润为 484,483,234.71 元。 根据中国证券监督管理委员会《关于进一步落实上市公司现金分红有关事项 的通知》、《上市公司监管指引第 3 号—上市公司现金分红（2023 年修订）》等 有关规定及《公司章程》的规定，按照截至公司年报披露日的总股本扣除回购专 户所持有股份数量测算，预计派发现金股利 5,95 ...

Financial Performance - The company's total revenue for 2024 was approximately ¥7.97 billion, a decrease of 0.85% compared to ¥8.03 billion in 2023[21]. - The net profit attributable to shareholders for 2024 was approximately ¥20.62 million, reflecting a 1.50% increase from ¥20.32 million in 2023[21]. - The net cash flow from operating activities increased by 94.56% to approximately ¥160.44 million in 2024, compared to ¥82.47 million in 2023[21]. - The basic earnings per share for 2024 was ¥0.0137, up 1.48% from ¥0.0135 in 2023[21]. - Total assets at the end of 2024 were approximately ¥16.01 billion, a decrease of 4.17% from ¥16.71 billion at the end of 2023[21]. - The net assets attributable to shareholders at the end of 2024 were approximately ¥5.54 billion, an increase of 1.65% from ¥5.45 billion at the end of 2023[21]. - The company reported a significant improvement in net profit excluding non-recurring items, which decreased to approximately -¥128.32 million in 2024 from -¥209.82 million in 2023, a 38.84% improvement[21]. - The fourth quarter revenue was approximately ¥1.91 billion, with a notable decline in net profit attributable to shareholders of -¥18.18 million[26]. - The company reported a non-operating income of approximately $148.94 million in 2024, a decrease of 35.3% compared to $230.14 million in 2023[28]. - The government subsidies related to normal business operations amounted to $2.37 million in 2024, down from $8.78 million in 2023, reflecting a decline of 73.1%[27]. - The fair value changes from financial assets and liabilities resulted in a gain of approximately $18.43 million in 2024, compared to a gain of $179.93 million in 2023, indicating a significant decrease of 89.8%[28]. Business Strategy and Operations - The company has actively expanded into the traditional Chinese medicine sector, aligning with national policy directions to enhance its market presence[35]. - The company is focusing on enhancing its supply chain services and digital platforms to improve customer engagement and operational efficiency[36]. - The implementation of the "two-invoice system" and centralized procurement policies is leading to increased industry concentration, benefiting larger pharmaceutical distribution companies[36]. - The company anticipates continued growth in the pharmaceutical sector despite challenges from policy adjustments and market competition[34]. - The government has introduced various supportive policies aimed at promoting the high-quality development of the pharmaceutical industry, which will guide the company's strategic initiatives[32]. - The company is focusing on optimizing its business structure in the medical device distribution sector, aiming to enhance profitability by reducing sales costs and shortening payment cycles[45]. - The company is expanding its sales scale of traditional Chinese medicine (TCM) products, leveraging its strong production capabilities and complete sales network in hospitals[45]. - The company is transitioning from traditional medical device distribution to upstream production and research and development, enhancing its presence in the in-vitro diagnostic device sector[46]. - The company is actively improving supply chain services and has transformed into a comprehensive medical supply chain service provider, creating new profit growth points[39]. - The company is leveraging big data analysis and process optimization to provide more precise and intelligent services to clients[37]. - The company is integrating online and offline services to provide more efficient and high-quality services to customers[39]. - The pharmaceutical and medical device distribution segment is the company's traditional business, focusing on providing comprehensive medical solutions and optimizing logistics to ensure timely delivery of products[48]. Market Trends and Projections - The healthcare expenditure in China is projected to reach approximately $90.58 billion in 2023, accounting for 7.2% of the GDP, indicating a stable growth in medical demand[34]. - The aging population in China is expected to reach 22% by 2024, with those aged 65 and above at 15.6%, driving sustained demand in the pharmaceutical industry[34]. - In 2024, the company achieved total revenue of 7.966 billion yuan and a net profit attributable to shareholders of 20.6216 million yuan, despite pressures from cost control and healthcare reform policies[47]. - The company is focusing on the development of high-end medical devices and innovative drugs, aiming for a full coverage of hospitals in Shandong province[60]. - The company is pursuing a strategic transformation towards a full healthcare industry chain, integrating upstream and downstream operations effectively[61]. Research and Development - Research and development expenses decreased by 31.38% to ¥10.03 million in 2024, down from ¥14.62 million in 2023[76]. - The company is focusing on independent R&D and has established a cross-departmental project management model to oversee the entire product lifecycle, enhancing collaboration across various functions[109]. - The strategic focus on the traditional Chinese medicine sector has led to the development of a complete industry chain from raw materials to innovative drugs and health products[110]. - The company has autonomously developed intelligent equipment for the liquefaction of traditional Chinese medicine, which has received government funding support of 9.5 million yuan for its key R&D project[111]. - The company is exploring potential acquisitions to enhance its product portfolio, with a budget of 500 million RMB allocated for this purpose[143]. Governance and Compliance - The company emphasizes the protection of shareholder rights and has established a governance structure including a shareholders' meeting, board of directors, supervisory board, and management team[176]. - The company strictly adheres to information disclosure obligations, ensuring that shareholders and creditors are informed of operational dynamics and financial status in a timely and accurate manner[177]. - The governance structure includes a board of directors with nine members, three of whom are independent directors, ensuring compliance with regulatory standards[117]. - The company has established an independent financial department with a complete financial accounting system, ensuring financial independence and compliance with relevant laws[130]. - The company has maintained stability in its executive team, with no resignations or dismissals reported during the current term[132]. - The independent directors have fulfilled their responsibilities and ensured the protection of minority shareholders' rights[163]. Employee and Talent Management - The total number of employees at the end of the reporting period is 2,897, with 301 in the parent company and 152 in major subsidiaries[157]. - The professional composition includes 1,172 sales personnel, 377 technical personnel, and 242 production personnel[157]. - The company has established a comprehensive salary and benefits system, along with a performance evaluation system to attract and retain talent[158]. - The company has implemented a comprehensive human resources management system to enhance employee training and development, focusing on cultivating a loyal workforce[180]. Social Responsibility and Sustainability - The company emphasizes its commitment to social responsibility, aiming to create value for shareholders while contributing to societal and environmental development[175]. - The company has established a goal-oriented energy-saving system, promoting resource conservation and recycling initiatives across its operations[185]. - The company is committed to social responsibility, encouraging employees to participate in charitable activities and maintaining good relations with government agencies[187]. - The company plans to adapt to economic changes and enhance its sustainable development capabilities by 2025, aiming for harmonious development with society[187]. Legal Matters - The company is involved in 15 ongoing lawsuits as the plaintiff, with a total amount of 346.25 million yuan at stake[199]. - As the defendant, the company is facing 34 lawsuits, with a total amount of 1.841755 billion yuan involved[199]. - The company has received favorable judgments in some cases, with amounts to be paid by the opposing party totaling 814.23 million yuan[199]. - The company has been ordered to pay 8.6071 million yuan in a concluded lawsuit where the judgment supported the opposing party's claims[199].

瑞康医药（002589）公告，2024年营业收入79.66亿元，同比下降0.85%。归属于上市公司股东的净利润 2062.16万元，同比增长1.50%。基本每股收益0.0137元/股，同比增长1.48%。以15.05亿股扣除回购专户 所持有股份为基数，向全体股东每10股派发现金红利0.04元(含税)，送红股0股(含税)，不以公积金转增 股本。 ...

证券代码：002589 证券简称：瑞康医药 公告编号：2025-016 瑞康医药集团股份有限公司 关于实际控制人部分股份解除质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导 性陈述或重大遗漏。 瑞康医药集团股份有限公司（以下简称"公司"）近日接到实际控制人张仁 一、本次解除质押的基本情况 二、股东所持股份累计被质押的情况 华女士的函告，获悉其所持有本公司的部分股份已解除质押，具体事项如下： | 股东名称 | 是否为第一 | 解除质押股数 | 质押开始日 | | 占其所 | 占公司总 | 质押解除 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 大股东及一 致行动人 | （万股） | 期 | | 持股份 比例 | 股本比例 | 日期 | 质权人 | | 张仁华 | 是 | 1705.76 | 2022 年 | 12 | 8.47% | 1.13% | 2025 年 4 | 烟台市财金发展投 | | | | | 月 14 | 日 | | | 月 16 日 | 资集团有限公司 | | 合计 | — ...

证券代码：002589 证券简称：瑞康医药 公告编号：2025-015 瑞康医药集团股份有限公司 关于回购公司股份比例达到 1%暨回购进展的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导 性陈述或重大遗漏。 瑞康医药集团股份有限公司（以下简称"公司"、"瑞康医药"）于 2024 年 11 月 7 日召开第五届董事会第十次会议，审议通过了《关于回购公司股份方案 的议案》，同意公司使用银行专项贷款资金及自有资金以集中竞价交易方式回购 公司部分已发行的人民币普通股（A 股），本次回购股份将用于实施员工持股计 划，回购股份的资金总额不低于人民币 10,000 万元（含），不超过人民币 20,000 万元（含），回购股份的价格不超过人民币 4.5 元/股（含），具体回购股份的 数量以回购期限届满或回购完毕时实际回购的股份数量为准，实施期限为董事会 审议通过回购股份方案之日起 12 个月内。具体内容详见公司于 2024 年 11 月 11 日在巨潮资讯网披露《第五届董事会第十次会议决议的公告》（2024-036）及 《关于回购公司股份方案暨取得金融机构股票回购专项贷款承诺函的公告》（公 ...

证券代码：002589 证券简称：瑞康医药 公告编号：2025-014 瑞康医药集团股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性 陈述或重大遗漏。 瑞康医药集团股份有限公司（以下简称"公司"、"瑞康医药"）于 2024 年 11 月 7 日召开第五届董事会第十次会议，审议通过了《关于回购公司股份方 案的议案》，同意公司使用银行专项贷款资金及自有资金以集中竞价交易方式回 购公司部分已发行的人民币普通股（A 股），本次回购股份将用于实施员工持 股计划，回购股份的资金总额不低于人民币 10,000 万元（含），不超过人民币 20,000 万元（含），回购股份的价格不超过人民币 4.5 元/股（含），具体回购 股份的数量以回购期限届满或回购完毕时实际回购的股份数量为准，实施期限为 董事会审议通过回购股份方案之日起 12 个月内。具体内容详见公司于 2024 年 11 月 11 日在巨潮资讯网披露《第五届董事会第十次会议决议的公告》（2024-036） 及《关于回购公司股份方案暨取得金融机构股票回购专项贷款承诺函的公告》（公 告编号：2024- ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002589 证券简称：瑞康医药 公告编号：2025-013 瑞康医药集团股份有限公司 更正公告 本公司及董事会全体成员保证公告内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 瑞康医药集团股份有限公司（以下简称"公司"）于2023年12月21日、2024年11月21日在巨潮资讯网刊登 了《关于拟变更会计师事务所的公告》（公告编号：2023-046）和《关于续聘会计师事务所的公告》 （公告编号：2024-042）。经事后复核，上述公告中中兴财光华会计师事务所（特殊普通合伙）诚信记 录信息有误，现予以更正如下： 更正前： 《关于拟变更会计师事务所的公告》（公告编号：2023-046） 一、拟变更会计师事务所的基本情况 （一）机构信息 5. 诚信记录 中兴财光华近三年因执业行为受到刑事处罚 0 次、行政处罚 6 次、监督管理措施 25 次、自律监管措施 0 次和纪律处分 3 次。66 名从业人员近三年因执业行为受到刑事处罚 0 次、行政处罚 6 次、监督管理措 施 25 次、自律监管措施 0 次和纪律处分 3 次。 《关于续聘会计师事务所的公告 ...